| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1464-5491.2003.01076.X |
| P698 | PubMed publication ID | 14632713 |
| P2093 | author name string | Zinman B | |
| Owens DR | |||
| Bolli G | |||
| P2860 | cites work | Inhaled human insulin treatment in patients with type 2 diabetes mellitus | Q31933826 |
| Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study | Q32040835 | ||
| Insulins today and beyond | Q34365284 | ||
| Biologically erodable microspheres as potential oral drug delivery systems | Q34423490 | ||
| Oral tolerance for the treatment of autoimmune diseases | Q41360651 | ||
| No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. | Q42493380 | ||
| Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients | Q43585442 | ||
| Phospholipid deformable vesicles for buccal delivery of insulin | Q44015111 | ||
| Insulin across respiratory mucosae by aerosol delivery | Q44323495 | ||
| Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. | Q46004509 | ||
| Insulin and C-peptide levels following oral administration of insulin in intestinal-enzyme protected capsules | Q46203821 | ||
| Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. | Q51554328 | ||
| Intranasal insulin therapy: the clinical realities | Q58169383 | ||
| P433 | issue | 11 | |
| P921 | main subject | preproinsulin | Q7240673 |
| P304 | page(s) | 886-898 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Diabetic Medicine | Q15758639 |
| P1476 | title | Alternative routes of insulin delivery | |
| P478 | volume | 20 |
| Q98771026 | A Review of the Impact of Smoking on Inhaled Insulin: Would You Stop Smoking if Insulin Can Be Inhaled? |
| Q35682776 | A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus |
| Q90354103 | Advances in transdermal insulin delivery |
| Q36666273 | Alternatives routes of insulin delivery. |
| Q57349418 | Biodegradable pH-Dependent Thermo-Sensitive Hydrogels for Oral Insulin Delivery |
| Q36316655 | Commercial challenges of protein drug delivery |
| Q40066204 | Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants |
| Q36316910 | Delivery of parathyroid hormone for the treatment of osteoporosis |
| Q34245943 | Design and in silico evaluation of an intraperitoneal-subcutaneous (IP-SC) artificial pancreas |
| Q38306418 | Developing accurate models of the human airways. |
| Q53679697 | Development and evaluation of chitosan and chitosan derivative nanoparticles containing insulin for oral administration. |
| Q46811016 | Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs |
| Q38201717 | Drug transport mechanism of oral antidiabetic nanomedicines |
| Q57120130 | Effect of oral insulin on diabetes-induced intestinal mucosal growth in rats |
| Q27024335 | Emerging Trends in Noninvasive Insulin Delivery |
| Q33527532 | Entrapment enhancement of peptide drugs in niosomes |
| Q51361274 | Evaluation of hepatic glucose metabolism via gluconeogenesis and glycogenolysis after oral administration of insulin nanoparticles. |
| Q36792525 | Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetes |
| Q40585395 | Ex vivo evaluation of insulin nanoparticles using chitosan and arabic gum. |
| Q35876380 | Exubera(®) (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes |
| Q51193134 | Formulation of two-layer dissolving polymeric microneedle patches for insulin transdermal delivery in diabetic mice. |
| Q21129334 | GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS |
| Q42557469 | Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells |
| Q38309884 | How to overcome the limitations of current insulin administration with new non-invasive delivery systems |
| Q90446971 | Hydrogels For Peptide Hormones Delivery: Therapeutic And Tissue Engineering Applications |
| Q39599106 | Hydrophobic ion pairing of an insulin-sodium deoxycholate complex for oral delivery of insulin. |
| Q37436438 | Impact of Absorption and Transport on Intelligent Therapeutics and Nano-scale Delivery of Protein Therapeutic Agents |
| Q39572372 | In pursuit of excellence in diabetes care: trends in insulin delivery |
| Q35826982 | Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System. |
| Q43259046 | Influence of polymers ratio on insulin-loaded nanoparticles based on poly-epsilon-caprolactone and Eudragit RS for oral administration |
| Q46390812 | Influence of stabilizers on the physicochemical characteristics of inhaled insulin powders produced by supercritical antisolvent process |
| Q36856384 | Inhaled human [rDNA origin] insulin, a novel formulation for diabetes mellitus |
| Q40138501 | Inhaled human insulin (Exubera(®)): its pharmacologic profile, efficacy and safety in the treatment of adults with diabetes mellitus. |
| Q36494600 | Inhaled human insulin (Exubera): a review of its use in adult patients with diabetes mellitus |
| Q36679610 | Inhaled insulin (Exubera): Combining efficacy and convenience. |
| Q36616573 | Inhaled insulin delivery--where are we now? |
| Q37802033 | Inhaled insulin: A model for pulmonary systemic absorption? |
| Q36096727 | Inhaled insulin: Exubera |
| Q36754100 | Inhaled insulins |
| Q43893344 | Insights in regulated bioanalysis of human insulin and insulin analogs by immunoanalytical methods |
| Q43180563 | Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation. |
| Q99565694 | Insulin-delivery methods for children and adolescents with type 1 diabetes |
| Q35682783 | Intradermal insulin delivery: a promising future for diabetes management |
| Q48823757 | Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy |
| Q33856010 | Laser-engineered dissolving microneedle arrays for transdermal macromolecular drug delivery |
| Q36521858 | Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities |
| Q45209104 | Metabolic control and body mass index in patients with type 1 diabetes on different insulin regimens |
| Q37819486 | Microneedles: a valuable physical enhancer to increase transdermal drug delivery |
| Q47909116 | Microspheres for the oral delivery of insulin: preparation, evaluation and hypoglycaemic effect in streptozotocin-induced diabetic rats |
| Q37039026 | Nanoparticle strategies for the oral delivery of insulin. |
| Q34360945 | Needle-free injection of insulin powder: delivery efficiency and skin irritation assessment |
| Q37242616 | New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations |
| Q38285092 | Newer devices and improved formulations of inhaled insulin. |
| Q46777949 | Niosomes with sorbitan monoester as a carrier for vaginal delivery of insulin: studies in rats |
| Q36349694 | Noninvasive delivery technologies: respiratory delivery of vaccines |
| Q38084736 | Noninvasive insulin delivery: the great potential of cell-penetrating peptides |
| Q48611030 | Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration |
| Q35743439 | Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in type 1 and 2 diabetic rats |
| Q36218161 | Novel preparation of PLGA/HP55 nanoparticles for oral insulin delivery |
| Q92832689 | Optimization of formulation for enhanced intranasal delivery of insulin with translationally controlled tumor protein-derived protein transduction domain |
| Q45250033 | Optimization of the fine particle fraction of a lyophilized lysozyme formulation for dry powder inhalation |
| Q37689833 | Oral insulin and buccal insulin: a critical reappraisal |
| Q48203947 | Oral insulin delivery: existing barriers and current counter-strategies |
| Q36659979 | Peptides targeting protein kinases: strategies and implications |
| Q30496354 | Pharmaceutical particle engineering via spray drying |
| Q30300391 | Pharmacokinetic Model of the Transport of Fast-Acting Insulin From the Subcutaneous and Intradermal Spaces to Blood |
| Q64075391 | Phospholipid complex based nanoemulsion system for oral insulin delivery: preparation, in vitro, and in vivo evaluations |
| Q39434951 | Pre-formulation and systematic evaluation of amino acid assisted permeability of insulin across in vitro buccal cell layers |
| Q58690877 | Preparation and Characterization of Water-Soluble Chitosan Microparticles Loaded with Insulin Using the Polyelectrolyte Complexation Method |
| Q53395753 | Preparation and evaluation of oleoyl-carboxymethy-chitosan (OCMCS) nanoparticles as oral protein carriers. |
| Q53739700 | Preparation, characterization and in vivo evaluation of pH-sensitive oral insulin-loaded poly(lactic-co-glycolicacid) nanoparticles. |
| Q38778988 | Pursuit of a perfect insulin. |
| Q45273755 | Quantitative estimation of the effects of bile salt surfactant systems on insulin stability and permeability in the rat intestine using a mass balance model |
| Q41694066 | Raman mapping of mannitol/lysozyme particles produced via spray drying and single droplet drying. |
| Q38243785 | Recent advances in childhood diabetes mellitus. |
| Q37472722 | Recent challenges in insulin delivery systems: a review |
| Q37628557 | Recent progress in mechanical artificial pancreas |
| Q38286395 | Receptor-mediated endocytosis of macromolecules and strategy to enhance their transport in alveolar epithelial cells |
| Q47992362 | Selection and education of patients for inhaled insulin. |
| Q37404491 | Serum insulin aspart concentrations following high-dose insulin aspart administered directly into the duodenum of healthy subjects: an open-labeled, single-blinded, and uncontrolled exploratory trial |
| Q50904654 | Stimuli-Responsive Delivery of Therapeutics for Diabetes Treatment. |
| Q38013190 | Strategies for non-invasive delivery of biologics |
| Q38803035 | The function and performance of aqueous aerosol devices for inhalation therapy |
| Q43287023 | Trypsin as a novel potential absorption enhancer for improving the transdermal delivery of macromolecules |
| Q37117105 | Use of transdermal drug formulations in the elderly |
| Q38566437 | Why most oral insulin formulations do not reach clinical trials. |
| Q81193485 | [Inhaled insulin: a model for pulmonary systemic absorption?] |
Search more.